GLYCAR T cells for Carcinoma

Phase-Based Estimates
1
Effectiveness
1
Safety
Houston Methodist Hospital, Houston, TX
Carcinoma+2 More
GLYCAR T cells - Genetic
Eligibility
18+
All Sexes
Eligible conditions
Carcinoma

Study Summary

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

See full description

Eligible Conditions

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Hepatocellular Carcinoma

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether GLYCAR T cells will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma. Measurement will happen over the course of 6 weeks.

15 years
Median T cell persistence
6 weeks
Number of Patients with Dose Limiting Toxicity
Percent of Patients with best response as either complete remission or partial remission

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Control
GLYCAR T cells + Fludarabine and Cytoxan

This trial requires 9 total participants across 2 different treatment groups

This trial involves 2 different treatments. GLYCAR T Cells is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

GLYCAR T cells + Fludarabine and CytoxanGPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
ControlNo treatment in the control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
Fludarabine
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 15 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 15 years for reporting.

Who is running the study

Principal Investigator
T. A.
Prof. Tannaz Armaghany, Assistant Professor
Baylor College of Medicine

Closest Location

Houston Methodist Hospital - Houston, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Carcinoma or one of the other 2 conditions listed above. There are 9 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
, is an indication for sorafenib Hepatocellular carcinoma which is unresectable, recurrent and/or metastatic, is an indication for sorafenib. show original
The Barcelona Clinic Liver Cancer (BCLC) staging system is a classification system used to describe the stage (extent) of a cancer, primarily hepatocellular carcinoma show original
A patient with a Child-Pugh-Turcotte (CPT) score of less than 8 is considered to have a mild form of liver disease. show original
A Karnofsky score of more than 60% indicates that a person is able to carry on most normal activities. show original
Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent
Procurement Eligibility
GPC3-positive HCC
Age >18 years
The life expectancy of a person with this condition is more than 12 weeks. show original

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes carcinoma?

Add answer

The data obtained from this study indicate that the most common causes of carcinoma in the city of Belo Horizonte are smoking cessation and ageing.

Unverified Answer

What are common treatments for carcinoma?

Add answer

There are many effective and nontoxic treatment options for carcinoma. Surgery is often avoided, but when performed, it is usually not complete because of the large size of individual tumors. Treatment is primarily directed to symptomatic relief and can include radiation therapy, embolization, chemotherapy, antibody therapy, hormone therapy, local and systemic surgery, and various other non-surgical treatment options. Treatment of individual tumors usually consists of several different modalities. Survival after diagnosis is highly variable, but it can be improved by early detection, improved treatment of metastases, and improved understanding of causation and treatment.

Unverified Answer

Can carcinoma be cured?

Add answer

In most cancer patients, there is no chance of cure after diagnosis, and most curable cancers do not appear until Stage 4. Curative therapy has a good rate of long term survival, even after the initial therapy has been for more than 2 years. However, most patients with cure will eventually relapse within 2 to 3 years.

Unverified Answer

What is carcinoma?

Add answer

Carcinoma is a family of neoplasms characterized by abnormal cell growth and proliferation. Cancers typically start as localized neoplasms in which cells invade and/or spread into adjacent or regional tissue. More rarely, a cancer can be a systemic (i.e., metastatic), or a life-threatening, disease requiring specialist care. To diagnose carcinoma, it is important to differentiate tumors from non-tumors. Carcinoma is a heterogeneous disease, which causes difficulties in diagnosis and prognosis.

Unverified Answer

How many people get carcinoma a year in the United States?

Add answer

Approximately 3 million people in the US get a diagnosis of cancer. Cancer remains the largest cause of death, accounting for over a third of deaths in men and nearly a half in women. People with cancer have a high risk of disease recurrence.

Unverified Answer

What are the signs of carcinoma?

Add answer

The most common symptom of carcinoma is a mass or lump in the body that expands over time. Carcinoma can be detected on examination by a physician. Tumors may require a biopsy.\n

Unverified Answer

Has glycar t cells proven to be more effective than a placebo?

Add answer

The current analysis provides weak support for an enhanced effect of this immunotherapeutic regimen. However, there was no strong evidence of either a trend or a statistically significant difference in overall OS. The clinical relevance of this treatment approach remains to be established.

Unverified Answer

How serious can carcinoma be?

Add answer

Carcinoma is the most common malignant tumor in the head and neck region, accounting for 38% of oral and oropharyngeal malignancies. Recent findings describes the clinical behaviour of carcinomas at the time of its initial diagnosis.

Unverified Answer

What are the latest developments in glycar t cells for therapeutic use?

Add answer

This review summarizes the current progress in t cell therapy for cancer, highlighting the role of B cell vaccination (in particular MVA tCell) and the most recent data from the use of engineered T cells.

Unverified Answer

How does glycar t cells work?

Add answer

[It can inhibit the activity of glycar lymphocytes and decrease the expression of CD3 CD8 on glycar CD4 T cells in the PBMC; inhibit the proliferation of Glycar CD4 T cells induced by the binding of TGF-β1 to TEC with CDR2(+) in vitro; and restrain the cell cycle of Glycar T cells induced by the binding of CDR1(+) with TGF-β1.] All of the above findings may be helpful in the development of targeted therapy against GIL.

Unverified Answer

What are the common side effects of glycar t cells?

Add answer

The most common side effects of GLP-1 were: dizziness, headache, nausea, vomiting, loss of appetite, abdominal bloating, and muscle spasms. The common side effects of GLP-1 were minimal and could be easily reversed by stopping the treatment or lowering the dose.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma by sharing your contact details with the study coordinator.